The $57M cash infusion strengthens Schrodinger's balance sheet and provides additional runway without dilution. Monitor for future milestone payments from Ajax's pipeline progress, which could add further upside. The deal also serves as a proof point for Schrodinger's platform value, potentially supporting a re-rating.
Price Chart
Executive Summary
Schrodinger received an approximately $57 million cash payment from Eli Lilly's acquisition of Ajax Therapeutics, a company Schrodinger co-founded. Schrodinger is also eligible for additional milestone payments tied to Ajax's clinical and regulatory progress. This provides a material non-operating cash infusion and validates Schrodinger's drug discovery platform.
Key Facts
- Schrodinger received approximately $57 million in cash from Eli Lilly's acquisition of Ajax Therapeutics.
- Schrodinger is eligible for additional cash payments upon achievement of specified clinical and regulatory milestones by Ajax.
- The payment is a direct result of Schrodinger's co-founding role in Ajax, validating its platform-based drug discovery model.
Financial Impact
Immediate cash inflow of approximately $57 million, with potential for additional undisclosed milestone payments.
Risk Factors
- Milestone payments are contingent on Ajax's clinical and regulatory success, which is uncertain.
- The $57M is a one-time event and does not reflect recurring revenue or operating performance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001490978-26-000059 |
| Document: 0001490978-26-000059-index-headers.html | 0001490978-26-000059 |
| Document: 0001490978-26-000059-index.html | 0001490978-26-000059 |
| Document: 0001490978-26-000059.txt | 0001490978-26-000059 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 29, 2026 17w ago | 8-K | $16.25 $29.23 | ▲ +79.88% | ▲ +77.06% | $26.72 (+64.43%) |
Jun 23, 2026 18w ago | 8-K | $15.33 $30.24 | ▲ +97.26% | ▲ +94.42% | $26.72 (+74.30%) |
May 20, 2026 22w ago | 8-K | $13.23 $17.40 | ▲ +31.52% | ▲ +27.22% | $26.72 (+101.97%) |
May 5, 2026 25w ago | 8-K | $12.98 $15.14 | ▲ +16.64% | ▲ +14.58% | $26.72 (+105.86%) |
Apr 16, 2026 27w ago | Insider Cluster | $12.06 $16.41 | ▼ −36.07% | ▼ −29.02% | $26.72 (−121.56%) |
Mar 4, 2026 34w ago | Insider Cluster | $13.12 $14.16 | ▲ +7.93% | ▼ −2.16% | $26.72 (+103.66%) |
Feb 25, 2026 34w ago | 8-K | $12.76 $13.30 | ▲ +4.23% | ▼ −3.94% | $26.72 (+109.40%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers